Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Clinical Features in a Danish Population-Based Cohort of Probable Multiple System Atrophy Patients

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Risk of Multiple System Atrophy and the Use of Anti-Inflammatory Drugs: A Danish Register-Based Case-Control Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Resting Heart Rate Is Not Associated with Cognitive Function

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Strategies to Improve Stroke Care Services in Low- and Middle-Income Countries: A Systematic Review

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Gene-Environment Interaction in Parkinson's Disease: Coffee, ADORA2A, and CYP1A2

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Atlas of the Global Burden of Stroke (1990-2013): The GBD 2013 Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Author Correction: Assessment of brain reference genes for RT-qPCR studies in neurodegenerative diseases

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Novel insights into cerebral palsy

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Risk of Multiple System Atrophy and the Use of Anti-Inflammatory Drugs: A Danish Register-Based Case-Control Study

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND: Multiple system atrophy (MSA) is a rare, sporadic and progressive neurodegenerative disorder. We aimed to describe the clinical features of Danish probable MSA patients, evaluate their initial response to dopaminergic therapy and examine mortality.

METHODS: From the Danish National Patient Registry, we identified 782 patients diagnosed with conditions potentially compatible with probable MSA (International Classification of Diseases, version 10 (ICD-10) codes G23.2, G23.8 and G23.9) during 1994-2009. Through medical record review, we narrowed our sample to 115 patients who fulfilled the criteria for probable MSA. We recorded clinical features, examined differences by MSA subtype and used Kaplan-Meier survival analysis to examine mortality.

RESULTS: The mean age at onset of patients with probable MSA was 60.2 years (range 36-75 years) and mean time to wheelchair dependency was 4.7 years (range 0-15 years). One-third of patients experienced a transient improvement in motor symptoms with use of levodopa. Median survival from disease onset was 6.9 years (range 1-16 years, 95% CI 6.3-7.5) with no apparent variation according to gender or subtype.

CONCLUSIONS: Our nationwide approach corroborated that MSA is associated with diverse and grave symptoms, only limited response to levodopa, and poor prognosis.

Original languageEnglish
JournalNeuroepidemiology
Volume46
Issue number4
Pages (from-to)261-7
Number of pages7
ISSN0251-5350
DOIs
Publication statusPublished - 2016

ID: 46418032